Incyte Corporation (INCY) Stock: Price, Forecast & Analyst Target
Incyte Corporation (INCY) — MoonshotScore 91/100 (Exceptional band), calculated Nov 18, 2026. Price $117.80 (-1.08%), as of the Nov 18, 2026 trading session; market cap $24.0B. Expected results Feb 9, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Incyte Corporation · INCY · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-12: Incyte is a commercial biopharmaceutical company whose marketed therapies already generate substantial profit and cash, rather than a development-stage business dependent on outside funding. The durability question is whether the Jakafi franchise can finance expansion through Opzelura and the pipeline before the forecast revenue path turns lower.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Incyte (INCY)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and a fortress balance sheet, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- EPS beat 6 of the last 8 reports
- expected results Feb 9, 2027
- Altman Z 10.78 · Piotroski F 6
Helping: business quality, balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 88 | Exceptional | |
| 96 | Exceptional | |
| 96 | Exceptional | |
| 96 | Exceptional | |
| 91 | Exceptional | |
| 91 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $117.80 | |
| Change on the day | -1.08% | |
| 52-week range | $89.25–$132.60 | |
| Market capitalisation | $24.0B | — |
| Price / earnings (trailing) | 56.71 | |
| Shares traded on the day | 1.21M | |
| Beta (volatility vs the S&P 500) | 0.78 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Incyte (INCY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Incyte (INCY), and what does it report?
Short answer · as of
Incyte researches, develops and markets therapies led by Jakafi, with Opzelura, Minjuvi and partnered economics adding other revenue streams.
Research dated 2026-09-12.
Jakafi treats blood disorders, while the broader portfolio and pipeline span additional cancers and immune-related conditions.
Reported revenue is not solely sales from owned medicines: it also includes royalties, milestones and contract revenue. Jakafi supplies most of the disclosed segment revenue, making prescription demand for that franchise far more consequential than the biotechnology label alone suggests.
What do the latest results show for Incyte (INCY)?
Research dated 2026-09-12.
Recent results accelerated from the preceding period: revenue, operating profit, net income and diluted earnings all rose sharply, while the latest release cleared consensus on revenue and earnings. The annual record also shows revenue reaching a new high and profit recovering strongly after a year of unusually heavy research spending.
The disclosed annual mix keeps that improvement anchored to Jakafi, with Opzelura meaningful but still much smaller. Management says expected Jakafi XR sales are already included in full-year Jakafi guidance, while additional-country launches and reimbursement expansion should produce modest initial revenue followed by stronger momentum.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $1.37B | $424M | $2.11 (diluted) |
| Q4 FY2025 | $1.51B | $299M | $1.46 (diluted) |
| Q1 FY2026 | $1.27B | $303M | $1.47 (diluted) |
| Q2 FY2026 | $1.67B | $586M | $2.81 (diluted) |
What are the financial strengths and risks for Incyte (INCY)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Incyte combines recurring operating cash generation with a cash and investment balance that greatly exceeds debt and total liabilities. Liquidity has climbed steadily across the reported history, while capital expenditure has remained modest relative to operating cash flow.
That financial capacity supports a research program whose spending can materially change reported profit. The business risk is concentration: if Jakafi weakens before Opzelura and pipeline assets close the gap, the cash cushion can absorb investment but cannot preserve the revenue base by itself.
What should you watch next at Incyte (INCY)?
Short answer · as of
The next earnings report is expected on Feb 9, 2027.
Research dated 2026-09-12.
The scheduled earnings release carries a consensus loss after a sustained run of profitable periods, despite an expected revenue level that remains substantial. Watch research and commercial spending, operating cash conversion and whether liquidity continues to build through that earnings reset.
Product mix matters beyond the immediate release. Jakafi XR execution, Opzelura’s contribution and reimbursement-supported launches need to broaden the commercial base before longer-range estimates reach their expected revenue retreat; the widening spread among those estimates signals increasing uncertainty around that transition.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Incyte compare with its peers?
Short answer
Incyte's score ranks 10th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Compared with development-stage biotechnology businesses, Incyte already funds research from a profitable commercial franchise and recurring operating cash flow. Compared with diversified pharmaceutical companies, its revenue base remains unusually dependent on Jakafi, with Opzelura smaller and royalties, milestones and contract revenue ancillary.
That combination creates unusual financial autonomy alongside pronounced product concentration. The balance sheet gives Incyte room to develop and commercialize additional therapies, but diversification must come from assets already connected to its research and commercial system rather than from leverage.
| Company | Price | Market value | Score |
|---|---|---|---|
| $68.29 Nov 18, 2026 | $16.7B | 98 5-pillar Nov 18, 2026 | |
| $577.34 Nov 18, 2026 | $24.6B | 97 5-pillar Nov 18, 2026 | |
| $270.33 Nov 18, 2026 | $17.7B | 96 5-pillar Nov 18, 2026 | |
| $941.25 Nov 18, 2026 | $59.2B | 96 5-pillar Nov 18, 2026 | |
| $315.34 Nov 18, 2026 | $9.34B | 96 5-pillar Nov 18, 2026 | |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $95.80 Nov 18, 2026 | $10.9B | 95 5-pillar Nov 18, 2026 | |
| $404.02 Nov 18, 2026 | $28.1B | 92 5-pillar Nov 18, 2026 | |
| $72.75 Nov 18, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| Incyte (INCY) — this page | $117.80 | $24.0B | 91 |
| $66.12 Nov 18, 2026 | $9.99B | 90 5-pillar Nov 18, 2026 | |
| $210.01 Nov 18, 2026 | $31.8B | 84 5-pillar Nov 18, 2026 | |
| $68.67 Nov 18, 2026 | $39.5B | 73 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $104.00 – $157.00
- Consensus target
- $136.47
- Median target
- $140.00
Consensus record · Captured .
Measured against a quoted price of $117.80 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 6, 2026
- Transactions
- 100
- Identified insiders
- 10
- Purchases
- 0
- Sales
- 26
- Other transactions
- 74
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held INCY in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.11% | $24.73M | Added +21.1% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Incyte (INCY)?
What Investors Ask About Incyte (INCY) — Healthcare
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why is Jakafi so important to Incyte?
Jakafi contributes most of Incyte’s disclosed segment revenue and therefore carries disproportionate influence over growth, profit and the funding available for research. Opzelura and partnered revenue broaden the mix, but they remain much smaller.
How does Opzelura change Incyte’s revenue mix?
Opzelura is the largest disclosed revenue source outside Jakafi, giving Incyte another owned commercial product with meaningful scale. Its current contribution broadens the portfolio without yet removing Jakafi concentration.
Can Jakafi cash generation fund Incyte’s pipeline without debt?
Operating cash flow has remained positive, liquidity has risen steadily and debt is minimal beside cash and investments. That position supports heavy research spending without making borrowing central to the current funding model.
What is management expecting from Jakafi XR?
Management expects Jakafi XR to contribute meaningful sales and has already incorporated that contribution into full-year Jakafi guidance. Delivery therefore supports the existing outlook rather than representing upside outside it.
What is the INCY stock price today?
The last price recorded for Incyte Corporation (INCY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the INCY price target?
The analyst consensus price target for Incyte Corporation (INCY), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com